US Congress Suspends Medical Device Tax through 2019

February 2, 2018: By Joan McKenna

US lawmakers have suspended the medical device tax through 2019 in a short-term spending bill passed Jan. 8.

The medical device tax imposes a 2.3 percent sales tax on products such as pacemakers, artificial joints, surgical gloves, and dental instruments. It exempts eyeglasses, contact lenses, hearing aids, wheelchairs, and other devices the public generally buys for individual use. The tax applies to imported products, as well as those produced in the US.

Congress initially suspended the medical device tax in December 2015 for a two-year period.

The tax was created by the Affordable Care Act of 2010 and took effect in 2013.

US tax officials noted in 2013 that compliance was an issue. In the first half of 2013, collections were only 76.1 percent of projections.

Overall, the IRS collected $1.4 billion in medical device taxes in 2013 and $1.9 billion in 2014.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility